A Study of IBI3032 in Healthy Participants
{ "A Study of IBI3032 in Healthy Participants", "This study is testing a new drug called IBI3032 in healthy volunteers. It's a Phase I study, which means researchers are mainly looking at how safe IBI3032 is and how your body handles it. You would receive either IBI3032 or a placebo (a pill with no active medicine). The main goal is to see how many people experience side effects or serious side effects within 15 days of taking the drug. To join, you need to be a healthy male or female between 18 and 65 years old, with normal lab test results. You cannot join if you have allergies to IBI3032 or related drugs, or certain heart, lung, or kidney conditions. About 32 healthy people are expected to participate.", "design": "This is a randomized, double-blind, placebo-controlled Phase I study. About 32 healthy participants will be divided into groups, with most receiving IBI3032 and some receiving a placebo.", "commitments": "You would go through a screening period of up to 4 weeks. If eligible, you would receive a single dose of IBI3032 or placebo, followed by a safety check-up period of 15 days.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will be followed for safety for 15 days after receiving the study drug.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of IBI3032 in Healthy Participants
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study DrugBaseline up to Day 15
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
- Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study DrugBaseline up to Day 15
A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
- Number of Participants with adverse events (AEs)Baseline up to Day 15
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.